Physician-scientist with experience spanning biomarker development and regulatory
submissions joins to expand Tapestri’s reach to guide therapeutic insights.
South San Francisco, Calif., October 9, 2025 — Mission Bio, a leader in single-cell multi-
omics for precision medicine, today announced the appointment of Zivjena Vucetic, M.D., Ph.D.,
as Chief Medical Officer. A physician-scientist with more than 15 years of experience in
diagnostics and emerging platforms, Dr. Vucetic has directed medical and scientific strategies
that move technologies from discovery to clinical settings, building regulatory confidence and
supporting adoption across multiple therapeutic areas.
Dr. Vucetic most recently served as Chief Medical Officer and Senior Vice President at
Beckman Coulter Diagnostics, where she directed medical strategy across a multibillion-dollar
global portfolio and advanced blood-based biomarker programs in Alzheimer’s and other
neurodegenerative diseases. At Karius, she built the clinical and regulatory foundation for an
infectious disease sequencing test that achieved FDA Breakthrough Device designation. She
has also held leadership roles at Clinical Genomics, Ortho Clinical Diagnostics and Fujirebio
Diagnostics, guiding end-to-end validation, payer engagement, and publication strategy while
building strong partnerships with pharma and academic consortia.
“Zivjena brings a proven record of translating breakthrough science into clinical adoption at
global scale,” said Brian Kim, Chief Executive Officer of Mission Bio. “Her leadership
strengthens our ability to deliver evidence and confidence to our partners as they bring precision
therapies to patients. With her expertise, Mission Bio is positioned to set the standard for how
single-cell multi-omics informs the next generation of drug development and clinical research.”
“Throughout my career, I have focused on building the clinical evidence and regulatory
confidence required to move new diagnostics from concept to adoption,” said Dr. Vucetic.
“Mission Bio’s single-cell multi-omics platform carries the same potential to shift standards in
precision medicine, and I am eager to help extend its impact across cancer, cell and gene
therapy, and therapeutic development.”
Mission Bio’s Tapestri Platform is deployed worldwide by biopharma and academic researchers
to detect rare cell populations, profile clonal heterogeneity, validate biomarkers, and support cell
and gene therapy pipelines. With recent innovations in tri-omics, sample multiplexing, and an
expanding Pharma Assay Development (PAD) service line, the company is extending its role
from discovery into translational and late-stage therapeutic development.
About Mission Bio
Mission Bio is the single-cell tri-omics leader. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods, such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-
generation medical treatments. With the Tapestri Platform, Mission Bio is setting the standard in
the field, contributing significantly to the progress of personalized medicine and targeted
therapies. To learn more about Mission Bio and the Tapestri Platform, please visit
missionbio.com.
Media Contact
